Dr. Wang leads the ASA Biopharma Section Scientific Working Group on “Statistical Perspectives on AI/ML in Pharmaceutical Product Development” and AbbVie’s enterprise AI/ML and clinical trial innovation initiatives, advancing machine learning and advanced analytics to enable smarter, more efficient clinical trial design and decision-making across clinical development.

​

He leads global drug development programs with a strong track record of regulatory filings and approvals, contributing to three blockbuster therapies—Eliquis, Rinvoq, and Onglyza—that have improved the lives of millions of patients worldwide.

Li Wang holds a PhD in Statistics from Virginia Tech and a Bachelor of Science (B.S.) in Applied Mathematics from Peking University. He is currently pursuing an Executive MBA at Northwestern University, Kellogg School of Management (2025–2027).